BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...syntaxin 5 (STX5) EXPERIMENTAL SYSTEM: Patient samples; cell culture; mice LICENSING STATUS: Unpatented; licensing status not applicable...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Dimercaprol and derivative for viper bite poisoning

...60% or 0%. When administered 15 minutes after venom injection, both chelators prolonged survival. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | May 23, 2020
Politics, Policy & Law

SURVEY: As companies return to workplace, testing will take a back seat to multiple safety measures

...since some measures -- such as limiting the number of people in elevators -- is not applicable...
BioCentury | Apr 28, 2020
Distillery Therapeutics

Nanoparticle delivery of bee venom peptide to induce antigen release from tumors

...nodes, suggesting that antitumor effects on distant tumors were due to systemic immune activation. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Growth-accommodating biomimetic prosthetic valves for congenital valve disease

...baseline diameter of 12 mm to up to 20 mm to accommodate animal growth. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Hyaluronic acid, collagen to prevent intervertebral disc degeneration after herniation

...spine and preserved torsional stiffness and torque range, indicators of function following disc repair. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sodium nitrite plus EDTA for bacterial infections

...titers. Next steps by Arch Biopartners Inc. (TSX-V:ARCH; OTCBB:FOIFF) include Phase I safety testing. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Treating colorectal cancer with Holdemanella biformis or its metabolic products

...rodentium for four weeks, or F. rodentium supernatant for two weeks, reduced tumor growth. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Supplementation with for alcoholic fatty liver disease

...evaluating applications for indications with the same underlying disease mechanism as alcoholic liver disease. TARGET/MARKER/PATHWAY: Not applicable...
BioCentury | Dec 19, 2019

Inhibiting the EIF4G1-EIF4E interaction to treat autism

...EIF4G1); eukaryotic translation initiation factor 4E (eIF4E) EXPERIMENTAL SYSTEM: Mice LICENSING STATUS: Unpatented; licensing status not applicable...
Items per page:
1 - 10 of 3683